Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia

Alabed, Samer; Sabouni, Ammar; Providência, Rui; Atallah, Edmond; Qintar, Mohammed; Chico, Timothy J. A.

doi:10.1002/14651858.cd005154.pub4

Cited by 21 publications

(30 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SVT occurred pre-anesthesia in patients in this study. The research group adopted the following points for all the study cases: (1) In this study, ECG, vital signs and hemodynamics were strictly monitored in all patients. (2) Patients with SVT pre-anesthesia and hemodynamic stability were selected.…”

Section: Svt Managementmentioning

confidence: 99%

“…Supraventricular tachycardia (SVT) is a common arrhythmia in the perioperative period, which is associated with adverse stimulus such as cardiovascular risk factors, emotional tension, hypoxia, CO 2 accumulation, hypokalemia, and pain [1,2]. Antiarrhythmic drugs, including amiodarone, digoxin, adenosine, verapamil and so on, have been considered the rst-line agent in SVT [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Supraventricular Tachycardia in Patients with Non-Cardiac Surgery by Dexmedetomidine During the Perioperative Period. A Randomized Trial

Xu¹,

X²,

Yang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Previous studies have shown that application of dexmedetomidine (Dex) combined anesthesia during surgery can significantly reduce cardiovascular system complications and mortality of patients with cardiac disease during the perioperative period. The aim of this study was to explore the therapeutic effect of Dex on perioperative supraventricular tachycardia (SVT) in adult patients with non-cardiac surgery.Methods: Forty-six patients with SVT undergoing elective non-cardiac surgery were randomly divided into two groups, intravenously infused Dex (Dex group, 1.0 µg/kg) or midazolam (midazolam group, 0.06 mg/kg) for 10 minutes, respectively. The observation indexes containing the treatment efficiency of SVT, heart rate (HR) and and heart rate variability (HRV) including normalized low frequency power (LFnorm), normalized high frequency power (HFnorm) and LFnorm/HFnorm were recorded.Results: Treatment rates of SVT were 21/23 (91.3%) in Dex group vs 2/23 (8.7%) in midazolam group (P<0.001). In Dex group, LFnorm and LFnorm/HFnorm were decreased, and HFnorm were elevated and HR were decreased after twenty-three patients infused Dex (P < 0.05). However, there was no difference for HFnorm, LFnorm and LFnorm/HFnorm in midazolam group (P > 0.05). Conclusion: Perioperative use of dexmedetomidine has a significant therapeutic effect for SVT, and its mechanism is related to adjust cardiac autonomic nervous system and has no obvious connection with sedation.Trial registration: This trial was registered at ClinicalTrials.gov. registry number: NCT04284150 on February 13, 2020.

show abstract

Section: Svt Managementmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Treatment of Supraventricular Tachycardia in Patients with Non-Cardiac Surgery by Dexmedetomidine During the Perioperative Period. A Randomized Trial

Xu¹,

X²,

Yang³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…We therefore performed a Cochrane systematic review update3 to incorporate new trials performed since a previous review in 2006 4. The review compared the effects of adenosine versus CCAs in terminating SVT (table 1).…”

Section: Introductionmentioning

confidence: 99%

Cochrane corner: adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia

Alabed

Providência

Chico

2018

Heart

Self Cite

View full text Add to dashboard Cite

show abstract

“…При их неэффективности рекомендовано внутривенное введение аденозинтрифосфорной кислоты. При отсутствии восстановления синусового ритма у больных с высокой частотой желудочковых сокращений возможно назначение недигидропиридиновых антагонистов кальция или бета-адреноблокаторов (БАБ) (рисунок 1) [6].…”

unclassified

Modern treatment of supraventricular tachycardia

Тарзиманова

Подзолков

2020

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Supraventricular tachycardia (SVT) is one of the most common arrhythmias. The prevalence of SVT varies widely in different countries and is 2,25 per 1,000 people in the general population. SVT reduce the quality of life of patients, and in some cases can worsen the prognosis. In patients with cardiovascular disease, the risk of SVT increases. Therapy of SVT is selected depending on the stability of hemodynamic and the QRS width. Until now, the treatment of SVT remains an urgent issue of modern cardiology, since despite the high effectiveness of catheter ablation, antiarrhythmic therapy plays an important role.

show abstract

Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia

Abstract: Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia.

Cited by 21 publications

References 32 publications

Treatment of Supraventricular Tachycardia in Patients with Non-Cardiac Surgery by Dexmedetomidine During the Perioperative Period. A Randomized Trial

Treatment of Supraventricular Tachycardia in Patients with Non-Cardiac Surgery by Dexmedetomidine During the Perioperative Period. A Randomized Trial

Cochrane corner: adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia

Modern treatment of supraventricular tachycardia

Contact Info

Product

Resources

About

Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia

Abstract: Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia.

Cited by 21 publications

References 32 publications

Treatment of Supraventricular Tachycardia in Patients with Non-Cardiac&nbsp;Surgery&nbsp;by Dexmedetomidine During the Perioperative&nbsp;Period. A Randomized Trial

Treatment of Supraventricular Tachycardia in Patients with Non-Cardiac&nbsp;Surgery&nbsp;by Dexmedetomidine During the Perioperative&nbsp;Period. A Randomized Trial

Cochrane corner: adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia

Modern treatment of supraventricular tachycardia

Contact Info

Product

Resources

About

Treatment of Supraventricular Tachycardia in Patients with Non-Cardiac Surgery by Dexmedetomidine During the Perioperative Period. A Randomized Trial

Treatment of Supraventricular Tachycardia in Patients with Non-Cardiac Surgery by Dexmedetomidine During the Perioperative Period. A Randomized Trial